| Pharmacist-provided medication therapy management (MTM) program impacts outcomes for employees with diabetes SL Pinto, J Kumar, G Partha, RA Bechtol Population health management 17 (1), 21-27, 2014 | 40 | 2014 |
| Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study F Morschhauser, S Dahiya, ML Palomba, A Martin Garcia-Sancho, ... Nature Medicine, 1-9, 2024 | 22 | 2024 |
| Improving the economic and humanistic outcomes for diabetic patients: making a case for employer-sponsored medication therapy management SL Pinto, J Kumar, G Partha, RA Bechtol ClinicoEconomics and Outcomes Research, 153-159, 2013 | 22 | 2013 |
| Patient and neurologist preferences in the United States for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment J Kumar, MJ Cambron-Mellott, T Tencer, O Will, MS Mackie, K Beusterien Patient preference and adherence, 1515-1527, 2021 | 10 | 2021 |
| Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes A Pandey, L Achrafie, P Kodjamanova, T Tencer, J Kumar Current Medical Research and Opinion 38 (9), 1531-1541, 2022 | 7 | 2022 |
| Comparative efficacy and safety of ozanimod and dimethyl fumarate for relapsing-remitting multiple sclerosis using matching-adjusted indirect comparison S Cohan, J Kumar, S Arndorfer, X Zhu, M Zivkovic, T Tencer CNS drugs 35, 795-804, 2021 | 7 | 2021 |
| Matching-adjusted indirect comparison (MAIC) of efficacy and safety of lisocabtagene maraleucel (liso-cel) and mosunetuzumab for the treatment (Tx) of third line or later (3L+ … LJ Nastoupil, A Bonner, P Wang, L Almuallem, J Desai, O Fasan, T Farazi, ... Blood 142, 2338, 2023 | 6 | 2023 |
| A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis A Cichewicz, T Tencer, K Gupte-Singh, S Egodage, H Burnett, J Kumar Advances in Therapy 40 (5), 2116-2146, 2023 | 6 | 2023 |
| Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study F Morschhauser, S Dahiya, ML Palomba, AM Garcia-Sancho, JLR Ortega, ... Nature medicine 30 (8), 2374, 2024 | 4 | 2024 |
| Systematic literature review of real-world evidence on dose escalation and treatment switching in ulcerative colitis H Singh, L Wilson, T Tencer, J Kumar ClinicoEconomics and Outcomes Research, 125-138, 2023 | 4 | 2023 |
| Patient and neurologist preferences in the UK for relapsing–remitting multiple sclerosis treatments: findings from a discrete choice experiment T Tencer, O Will, J Kumar, MJ Cambron-Mellott, DMS Mackie, ... Current Medical Research and Opinion 37 (9), 1589-1598, 2021 | 4 | 2021 |
| Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis S Cohan, T Tencer, S Arndorfer, X Zhu, M Zivkovic, J Kumar Multiple Sclerosis and Related Disorders 52, 102972, 2021 | 3 | 2021 |
| Number-needed-to-treat analysis and risk-benefit assessment of Ozanimod compared with first-line disease-modifying therapies for relapsing-remitting multiple sclerosis J Kumar, T Tencer, E Swallow, O Patterson-Lomba, C Carley, ... MULTIPLE SCLEROSIS JOURNAL 25, 883-883, 2019 | 2 | 2019 |
| PDB53 SHORT-TERM OUTCOMES FOR AN EMPLOYER SPONSERED PHARMACIST-PROVIDED MULTI CENTER DIABETES MANAGEMENT PROGRAM S Pinto, J Kumar Value in Health 3 (12), A107, 2009 | 2 | 2009 |
| Evaluation of work productivity and activity impairment in moderate-to-severe ulcerative colitis participants treated with ozanimod in the phase 3 True North study L Floden, TP Pham, J Kumar, B Becker, JW Shaw, T Tencer JOURNAL OF CROHNS & COLITIS 16, I441-I442, 2022 | 1 | 2022 |
| POSB17 Ozanimod for the treatment of biologic-experienced patients with moderate-to-severe ulcerative colitis: results from a systematic literature review and network meta-analyses K Eaton, C Duperrouzel, P Bhandari, S Craigie, A Bonner, C Cameron, ... Value in Health 25 (1), S27-S28, 2022 | 1 | 2022 |
| S3307 Unmet need of an oral treatment in moderate to severe ulcerative colitis: findings from international patient and physician survey J Choi, R Lukanova, H Ahmad, J Kumar, M Osterman, K Davé, L Massey, ... Official journal of the American College of Gastroenterology| ACG 116, S1363, 2021 | 1 | 2021 |
| DOP69 Ozanimod for induction treatment of Moderate-to-Severe Ulcerative Colitis: Results from a systematic literature review and network meta-analyses K Eaton, C Duperrouzel, P Bhandari, S Craigie, A Bonner, C Cameron, ... Journal of Crohn's and Colitis 15 (Supplement_1), S103-S105, 2021 | 1 | 2021 |
| Comparative effectiveness of ozanimod versus dimethyl fumarate: results of a matching-adjusted indirect comparison S Cohan, J Kumar, S Arndorfer, X Zhu, M Zivkovic, T Tencer MULTIPLE SCLEROSIS JOURNAL 26 (3_ SUPPL), 140-140, 2020 | 1 | 2020 |
| PND9 Comparative Efficacy and Safety of Ozanimod Versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Matching-Adjusted Indirect Comparison S Cohan, J Kumar, S Arndorfer, X Zhu, M Zivkovic, T Tencer Value in Health 23, S624, 2020 | 1 | 2020 |
